Chidamide is a selective class I and IIb histone deacetylase inhibitor approved in China for relapsed or refractory peripheral T-cell lymphoma, representing the first benzamide-class HDAC inhibitor to reach the market. Simson Pharma's Chidamide reference standard and impurities support analytical development for this targeted epigenetic oncology agent.

Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Chidamide Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.